The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
U.S. President Donald Trump's latest tariff increase — and Beijing's plans to counter them — are hitting U.S. companies in China, according to a joint survey this month by...China Economyread more
"We are also constantly watching whether the trade war will turn into a tech war," Ma said Tuesday, according to a CNBC translation of his Chinese remarks published by a locak...China Economyread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
Talks between the world's two largest economies have stalled after each nation lobbied higher tariffs on the other's imports.Traderead more
"Pretty much the entire suite of apps that 'talk' over the internet could be vulnerable," said Tom Uren, a senior analyst at the Australian Strategic Policy Institute's...Cybersecurityread more
A Chinese official in Hong Kong is urging the quick passage of legal measures to allow fugitives to be transferred to the mainland.China Politicsread more
GAC Motor said its delaying its launch in the U.S. but had no timeline when it could launch there.Autosread more
The U.S. administration is considering limits to Chinese video surveillance firm Hikvision's ability to buy U.S. technology, the New York Times reported on Tuesday, deepening...World Politicsread more
Eli Lilly on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.
Shares of the company, which raised its quarterly dividend by 15 percent, rose 3.3 percent to $110 in early trading.
Lilly has been banking on 10 new drugs launched since 2014, including Trulicity and the recently approved migraine drug Emgality, to drive growth as some of its older treatments such as erectile dysfunction drug Cialis lose patent exclusivity.
"These 10 medicines are launching in some of the fastest growing categories and continue to deliver growth through increased volume, not price," Chief Financial Officer Joshua Smiley said in a statement.
Trulicity, for instance, recently overtook Humalog to become Lilly's top-selling medicine with sales of $816.2 million, and helped power the company's profit beat in the third quarter.
Lilly is also refocusing on high-profit areas such as cancer, as well as building up a strong pipeline.
The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine.
Lilly also said it aimed to decrease the time taken from identifying a target to clinical testing to about three years.
The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with analysts' average estimate of $5.82, according to IBES data from Refinitiv.
Lilly said revenue was expected to be between $25.3 billion and $25.8 billion for the coming year, also above estimate of $24.77 billion.
The Indianapolis-based company reiterated its forecast for 2018 adjusted profit.